In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors resulting in elimination of the provisional diagnostic categories of Hairy Cell Leukemia Variant (HCLv) and B Prolymphocytic Leukemia.
In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential.
In addition to earning the sixth spot nationally in Psychiatry, Yale New Haven Hospital ranked well in Obstetrics and Gynecology (#19), Otolaryngology (Ear Nose and Throat) (#27), Geriatrics (#28), Diabetes and Endocrinology (#29) Pulmonology and Lung Surgery (#31), Urology (#31), Heart and Heart Surgery (#43) Cancer (#45), Neurology and Neurosurgery (#48) and Gastroenterology and GI Surgery (#50).
The University of Texas MD Anderson Cancer Center today was ranked number one in the nation for cancer care in U.S. News & World Report’s 2024-25 "Best Hospitals" survey. Since the survey's inception in 1990, MD Anderson has consistently been one of the top two hospitals in the nation for cancer care, and it has maintained the top ranking for the past 10 years.
Sneaking by cancer’s defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM).
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T cell, and a helper T cell, researchers at MSK and Baylor College of Medicine have found. The discovery could alter the way doctors administer immunotherapies.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.
The University of New Mexico Comprehensive Cancer Cancer Center achieves accreditation for radiation oncology services from the American Society for Radiation Oncology APEx - Accreditation Program for Excellence
RWJBarnabas Health, the largest, most comprehensive academic health care system in New Jersey, along with Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, have named Gerardo Capo, MD, as the Medical Director of Trinitas Comprehensive Cancer Center at Trinitas Regional Medical Center, an RWJBarnabas Health facility.
Recent advances in medical technology now allow experts to treat benign thyroid nodules using a minimally invasive, non-surgical treatment known as thyroid radiofrequency ablation (RFA). Dr. Toni Beninato, MD, MS, FACS, an endocrine surgeon in the Endocrine and Neuroendocrine Tumor Program at Rutgers Cancer Institute and RWJBarnabas Health shares more.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Sarcomas are a rare and diverse group of cancers that arise in the bones and soft tissues, often referred to as 'the forgotten cancer.' Rutgers Cancer Institute and RWJBarnabas Health expert Dr. Adam Berger shares more information on the disease during sarcoma awareness month.
"North American Cancer Center Clinical Research Capacity and Benchmarking in the Post-Pandemic Era" was published July 1 in JCO Oncology Practice, an American Society of Clinical Oncology (ASCO) Journal.
Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.
Fred Hutch Cancer Center has launched (PS2@FH), a new summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.
• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).
MD Anderson and Rice announced the creation of the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment.
A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right